Result of GM

29 June 2021

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")

Result of GM

Cizzle Biotechnology, a UK based developer of a blood test for the early detection of a majority of the different forms of lung cancer, announces that at the General Meeting ("GM") of the Company held earlier today, all resolutions were voted on by a poll and were passed.

The votes cast in respect of the resolutions were as follows:

Enquiries:

About the Company

Cizzle Biotechnology is developing a blood test for the early detection of a majority of the different forms of lung cancer.  Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues.  Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early stage lung cancer.

For more information please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.